SI1670444T1 - Uporaba derivatov indolocetne kisline, ki zvišajo serumsko raven IGF-1,za pripravo terapevtskega sestavka za zdravljenje različnih bolezni - Google Patents
Uporaba derivatov indolocetne kisline, ki zvišajo serumsko raven IGF-1,za pripravo terapevtskega sestavka za zdravljenje različnih bolezniInfo
- Publication number
- SI1670444T1 SI1670444T1 SI200332019T SI200332019T SI1670444T1 SI 1670444 T1 SI1670444 T1 SI 1670444T1 SI 200332019 T SI200332019 T SI 200332019T SI 200332019 T SI200332019 T SI 200332019T SI 1670444 T1 SI1670444 T1 SI 1670444T1
- Authority
- SI
- Slovenia
- Prior art keywords
- preparation
- treatment
- composition
- level
- increase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/168—Steroids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/184—Hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2003/011171 WO2005039546A2 (en) | 2003-10-03 | 2003-10-03 | Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases |
EP03757934A EP1670444B1 (en) | 2003-10-03 | 2003-10-03 | Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1670444T1 true SI1670444T1 (sl) | 2011-09-30 |
Family
ID=34429223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200332019T SI1670444T1 (sl) | 2003-10-03 | 2003-10-03 | Uporaba derivatov indolocetne kisline, ki zvišajo serumsko raven IGF-1,za pripravo terapevtskega sestavka za zdravljenje različnih bolezni |
Country Status (16)
Country | Link |
---|---|
US (2) | US9408405B2 (sl) |
EP (1) | EP1670444B1 (sl) |
JP (1) | JP4641942B2 (sl) |
CN (1) | CN1938018B (sl) |
AT (1) | ATE506948T1 (sl) |
AU (1) | AU2003273967A1 (sl) |
CA (1) | CA2541090C (sl) |
CY (1) | CY1116665T1 (sl) |
DE (1) | DE60336934D1 (sl) |
DK (1) | DK1670444T3 (sl) |
ES (2) | ES2365847T3 (sl) |
HK (1) | HK1103963A1 (sl) |
PT (2) | PT1670444E (sl) |
RU (1) | RU2345552C2 (sl) |
SI (1) | SI1670444T1 (sl) |
WO (1) | WO2005039546A2 (sl) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2541126A1 (en) | 2003-10-03 | 2005-04-21 | Veijlen N.V. | Animal feed composition |
US9408405B2 (en) | 2003-10-03 | 2016-08-09 | Veijlen N.V. | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals |
WO2005049006A1 (ja) * | 2003-11-21 | 2005-06-02 | Ajinomoto Co., Inc. | 糖尿病治療剤 |
PT2118123E (pt) | 2007-01-31 | 2016-02-10 | Harvard College | Péptidos de p53 estabilizados e suas utilizações |
WO2008121767A2 (en) | 2007-03-28 | 2008-10-09 | President And Fellows Of Harvard College | Stitched polypeptides |
US9063122B2 (en) * | 2008-10-17 | 2015-06-23 | Alfredo Gallegos | Biomodulators for treatment or prevention of disease |
DK2440206T3 (en) | 2009-06-11 | 2018-11-05 | Dsm Ip Assets Bv | Trigonellin as a muscle stimulant |
US9790186B2 (en) | 2009-07-21 | 2017-10-17 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
RU2582678C2 (ru) | 2010-08-13 | 2016-04-27 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы |
TWI643868B (zh) | 2011-10-18 | 2018-12-11 | 艾利倫治療公司 | 擬肽巨環化合物 |
EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES |
JP6450191B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス,インコーポレイテッド | ペプチドミメティック大環状化合物 |
WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
WO2014080640A1 (ja) * | 2012-11-26 | 2014-05-30 | 国立大学法人東北大学 | エリスロポエチン発現増強剤 |
RU2524634C1 (ru) * | 2013-06-25 | 2014-07-27 | Государственное научное учреждение Северо-Кавказский зональный научно-исследовательский ветеринарный институт (ГНУ СКЗНИВИ) Российской академии сельскохозяйственных наук | Способ стимуляции роста птицы |
MX371329B (es) * | 2013-12-19 | 2020-01-27 | Puretein Bioscience Llc | Factor de creciemiento similar a la insulina (igf) activo y su uso en infecciones por el virus del síndrome reproductivo y respiratorio porcino (prrsv). |
KR102265412B1 (ko) * | 2014-08-13 | 2021-06-14 | 주식회사 엘지생활건강 | 그라민 또는 이의 약학적으로 허용가능한 염을 포함하는 피부 미백, 탄력, 주름개선, 보습 또는 항염증용 화장료 또는 약학 조성물 |
KR20170058424A (ko) | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
EP3233109A4 (en) * | 2014-12-16 | 2018-07-18 | Puretein Bioscience, LLC | Methods for increasing serum igf-1 in an animal |
JP2018516844A (ja) | 2015-03-20 | 2018-06-28 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | ペプチド模倣大環状分子およびその使用 |
WO2017035288A1 (en) * | 2015-08-27 | 2017-03-02 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
US11701348B1 (en) | 2016-07-23 | 2023-07-18 | Turtle Bear Holdings, Llc | Psilocybin compositions |
US20210069170A1 (en) | 2016-07-23 | 2021-03-11 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
JP7475702B2 (ja) * | 2018-12-13 | 2024-04-30 | エイム・イムノテック・インコーポレイテッド | 筋痛性脳脊髄炎患者における運動耐容能を改善する方法 |
WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
CN111407884B (zh) * | 2019-06-24 | 2021-12-07 | 浙江大学 | 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途 |
WO2021051130A1 (en) * | 2019-09-09 | 2021-03-18 | The University Of Chicago | Combination therapy for the treatment of migraines |
JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス, インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
CA3158059A1 (en) | 2019-11-19 | 2021-05-27 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
US20230219889A1 (en) | 2020-05-19 | 2023-07-13 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
WO2022047580A1 (en) * | 2020-09-01 | 2022-03-10 | Magicmed Industries Inc. | Hydroxylated psilocybin derivatives and methods of using |
CN112138028A (zh) * | 2020-10-10 | 2020-12-29 | 南京中医药大学 | 蟾蜍色胺类物质在制备抗抑郁药物中的应用 |
CN114870018A (zh) * | 2022-05-12 | 2022-08-09 | 江南大学 | 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用 |
CN115813918B (zh) * | 2022-09-30 | 2024-04-02 | 中国药科大学 | 吲哚乙酸在制备抑郁症治疗药物中的应用 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA957281A (en) * | 1970-02-03 | 1974-11-05 | Nathan N. Share | Pharmaceutical compositions containing indole-3-acetic acid derivatives as a skeletal muscle stimulant |
US4025650A (en) * | 1975-11-24 | 1977-05-24 | Control Drug, Inc. | Method and composition for preventing nutritional deficiency |
GB1475861A (en) | 1976-03-19 | 1977-06-10 | Warner Lambert Co | Pharmaceutical composition |
GB1535778A (en) | 1976-12-06 | 1978-12-13 | Mac Sweeney D | Compounds useful in treatment of unipolar depression |
JPS60199801A (ja) | 1984-03-24 | 1985-10-09 | Masaki Kamata | 動物に対する植物成長ホルモンの投与方法 |
US4687763A (en) | 1985-02-25 | 1987-08-18 | Massachusetts Institute Of Technology | Composition and method for increasing levels or release of brain serotonin |
US4650789A (en) * | 1985-10-15 | 1987-03-17 | Commonwealth Medical Corporation Of America | Method and composition for increasing production of serotonin |
BE1000990A3 (nl) | 1987-10-09 | 1989-05-30 | Picanol Nv | Inrichting voor het op elkaar aansluiten van onderling verplaatsbare elementen, en transportinrichting die eerstgenoemde inrichting toepast. |
GB8727099D0 (en) * | 1987-11-19 | 1987-12-23 | Cellena Cell Eng A G | Compositions containing melantonin/homologues |
US4945103A (en) | 1989-01-17 | 1990-07-31 | Michael Cohen | Method of treating pre-menstrual syndrome |
IT1237472B (it) | 1989-10-04 | 1993-06-07 | Polifarma Spa | Derivati di acido 3-indolpiruvico, loro procedimento di produzione ed impiego terapeutico. |
US5132113A (en) * | 1990-10-26 | 1992-07-21 | Maurizio Luca | Nutritional composition containing essential amino acids |
US5192753A (en) * | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
CA2116036A1 (en) * | 1991-10-18 | 1993-04-29 | F. Eugene Yates | Device for the transdermal administration of melatonin |
GB9214419D0 (en) | 1992-07-07 | 1992-08-19 | Concannon Peter | Biocidal agents |
JPH0725838A (ja) * | 1993-05-13 | 1995-01-27 | Yotsuba Yuka Kk | 疲労の予防または回復のための経口投与剤 |
JP3541969B2 (ja) | 1994-09-29 | 2004-07-14 | 東洋紡績株式会社 | ベットマット |
JP3617102B2 (ja) * | 1995-01-27 | 2005-02-02 | 味の素株式会社 | ヒト筋肉疲労の早期回復効果を有するアミノ酸栄養組成物 |
JPH08308580A (ja) * | 1995-05-17 | 1996-11-26 | Takeda Chem Ind Ltd | 組換え型ヒトghrhレセプター蛋白質、その製造法および用途 |
EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
FR2741799B1 (fr) * | 1995-12-04 | 1998-01-02 | Oreal | Utilisation de melatonine dans une composition pour traiter les signes cutanes des etats de fatigue |
WO1997025060A1 (fr) * | 1996-01-09 | 1997-07-17 | The Institute Of Physical And Chemical Research | Compositions d'acides amines |
FR2746313B1 (fr) | 1996-03-22 | 1998-04-17 | Adir | Utilisation de la melatonine et des ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention et au traitement du diabete et des complications diabetiques |
US5958964A (en) | 1997-02-18 | 1999-09-28 | South Alabama Medical Science Foundation | Use of melatonin to prevent cytotoxic effects of amyloid beta protein |
DE19739763A1 (de) | 1997-09-10 | 1999-09-23 | Franz Uhl | Vitamin B3/Niacin zur Behandlung von Krankheiten |
US6017946A (en) * | 1997-10-08 | 2000-01-25 | Posner; Robert | Serotonin containing formulation for oral administration and method of use |
EP1159292A2 (en) * | 1998-08-14 | 2001-12-05 | Administrators of The Tulane Educational Fund | Compounds having growth hormone releasing activity |
US7304029B1 (en) | 1998-09-03 | 2007-12-04 | Neuren Pharmaceuticals Ltd. | Neuroprotective effect of growth hormone |
IL132366A0 (en) | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
CN1069050C (zh) | 1998-12-01 | 2001-08-01 | 周旭生 | 一种治疗糖尿病的中药复方制剂 |
ATE285769T1 (de) | 1998-12-04 | 2005-01-15 | Neurosearch As | Verwendung von isatinderivaten als ionenkanalaktivierende mittel |
FR2795323B1 (fr) | 1999-06-23 | 2001-11-16 | Adir | Utilisation de ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention ou au traitement des pathologies du systeme gastrointestinal |
CN1088597C (zh) * | 1999-10-26 | 2002-08-07 | 合肥永生制药有限公司 | 尿多酸肽组合物及其用途 |
US20020155163A1 (en) * | 1999-12-27 | 2002-10-24 | Samuel D. Benjamin | Integrated multi-vitamin and mineral combination |
AU2001238718A1 (en) | 2000-03-02 | 2001-09-12 | The Institutes For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
DE10037773C1 (de) * | 2000-08-03 | 2002-08-22 | Hennecke Gmbh | Verfahren und Vorrichtung zum Herstellen von mit Langfasern verstärkten Kunststoff-Formteilen |
DE10109798A1 (de) | 2001-03-01 | 2002-09-12 | Aventis Pharma Gmbh | Gesundheitsfördernde Zusammensetzung von Verbindungen |
US20030166554A1 (en) * | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
JP2002281914A (ja) | 2001-03-27 | 2002-10-02 | Nishi Nippon Green Kk | 魚類、家畜類の栄養活力促進剤の製造方法 |
US20020147155A1 (en) * | 2001-04-06 | 2002-10-10 | Foster Warren G. | Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands |
CN1408397A (zh) | 2001-09-26 | 2003-04-09 | 北京本元青阳生物科技发展有限公司 | 含褪黑素和益智中药的组合物 |
JP2003137808A (ja) * | 2001-10-26 | 2003-05-14 | Kakunai Juyotai Kenkyusho:Kk | 新規経腸栄養剤の製造法 |
WO2003080068A1 (en) | 2002-03-18 | 2003-10-02 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative |
CN1440744A (zh) | 2003-02-15 | 2003-09-10 | 高景曦 | 纳米包覆退黑激素复合保健品 |
US7592361B2 (en) | 2003-04-28 | 2009-09-22 | Bayer Pharmaceuticals Corporation | Indole acetic acid derivatives and their use as pharmaceutical agents |
US9408405B2 (en) | 2003-10-03 | 2016-08-09 | Veijlen N.V. | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals |
CA2541126A1 (en) | 2003-10-03 | 2005-04-21 | Veijlen N.V. | Animal feed composition |
-
2003
- 2003-10-03 US US10/574,467 patent/US9408405B2/en active Active
- 2003-10-03 SI SI200332019T patent/SI1670444T1/sl unknown
- 2003-10-03 JP JP2005509805A patent/JP4641942B2/ja not_active Expired - Fee Related
- 2003-10-03 PT PT03757934T patent/PT1670444E/pt unknown
- 2003-10-03 DE DE60336934T patent/DE60336934D1/de not_active Expired - Lifetime
- 2003-10-03 AU AU2003273967A patent/AU2003273967A1/en not_active Abandoned
- 2003-10-03 WO PCT/EP2003/011171 patent/WO2005039546A2/en active Application Filing
- 2003-10-03 AT AT03757934T patent/ATE506948T1/de active
- 2003-10-03 ES ES03757934T patent/ES2365847T3/es not_active Expired - Lifetime
- 2003-10-03 CN CN2003801105778A patent/CN1938018B/zh not_active Expired - Fee Related
- 2003-10-03 DK DK03757934.9T patent/DK1670444T3/da active
- 2003-10-03 CA CA2541090A patent/CA2541090C/en not_active Expired - Lifetime
- 2003-10-03 EP EP03757934A patent/EP1670444B1/en not_active Expired - Lifetime
-
2004
- 2004-09-28 PT PT04765746T patent/PT1667678E/pt unknown
- 2004-09-28 RU RU2006114743/13A patent/RU2345552C2/ru active
- 2004-09-28 ES ES04765746T patent/ES2326595T3/es active Active
-
2007
- 2007-07-27 HK HK07108228.0A patent/HK1103963A1/xx not_active IP Right Cessation
-
2011
- 2011-07-26 CY CY20111100732T patent/CY1116665T1/el unknown
-
2016
- 2016-07-06 US US15/203,671 patent/US10716778B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2326595T3 (es) | 2009-10-15 |
WO2005039546A2 (en) | 2005-05-06 |
CN1938018B (zh) | 2010-09-01 |
DE60336934D1 (de) | 2011-06-09 |
US9408405B2 (en) | 2016-08-09 |
HK1103963A1 (en) | 2008-01-04 |
AU2003273967A1 (en) | 2005-05-11 |
US20080194553A1 (en) | 2008-08-14 |
CY1116665T1 (el) | 2017-03-15 |
RU2345552C2 (ru) | 2009-02-10 |
CA2541090A1 (en) | 2005-05-06 |
US10716778B2 (en) | 2020-07-21 |
CA2541090C (en) | 2013-04-16 |
EP1670444B1 (en) | 2011-04-27 |
AU2003273967A8 (en) | 2005-05-11 |
CN1938018A (zh) | 2007-03-28 |
RU2006114743A (ru) | 2007-11-10 |
JP2007525405A (ja) | 2007-09-06 |
EP1670444A2 (en) | 2006-06-21 |
DK1670444T3 (da) | 2011-08-22 |
WO2005039546A3 (en) | 2007-10-04 |
PT1670444E (pt) | 2011-07-29 |
JP4641942B2 (ja) | 2011-03-02 |
PT1667678E (pt) | 2009-08-05 |
ES2365847T3 (es) | 2011-10-11 |
US20160331725A1 (en) | 2016-11-17 |
ATE506948T1 (de) | 2011-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003273967A8 (en) | Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases | |
MXPA05009933A (es) | Composiciones que comprenden acidos grasos y aminoacidos. | |
EP1784388B8 (en) | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | |
MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
IL161154A0 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
IL159960A (en) | Indane acetic acid derivatives, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments | |
EA200501710A1 (ru) | Замещённые карбоновые кислоты | |
RU2007117492A (ru) | Применение органических соединений | |
RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
JP2010111646A (ja) | 潰瘍性大腸炎治療剤 | |
WO2019098811A2 (ko) | Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 | |
CN1287855C (zh) | B型慢性肝炎治疗剂 | |
KR100483328B1 (ko) | 피로 회복 기능을 가지는 조성물 및 그 제조 방법과 이를이용한 피로 회복제 | |
JP4931306B2 (ja) | 骨形成を安全に促進させる医薬複合剤 | |
WO2001051489A3 (en) | Methods for lowering uric acid levels | |
CN1488368A (zh) | 鼻炎清 | |
CN1566086A (zh) | 一种氨基酸螯合钙及其制剂和应用 | |
CN1201769C (zh) | 治疗糖尿病、肾病的药物 | |
TW200600094A (en) | Pharmaceutical compositions for prevention or treatment of disorders of lipid metabolism | |
CN1150005C (zh) | 用于治疗癣疮的外用药剂 | |
CN1187046C (zh) | 治疗肾病的酮酸制剂 | |
CN1180775C (zh) | 复方口腔溃疡胶囊 | |
Saini | Oral sex and oral cancer: A virus link | |
JP2022011232A (ja) | タンパク質合成阻害抑制剤 |